Anlotinib is effective in the treatment of advanced carcinoma ex pleomorphic adenoma of the submandibular gland

This article was published in the following Dove Press journal:
OncoTargets and Therapy

Shujie Song*
Ping Sui*
Minmin Li
Liangming Zhang
Dengjun Sun

Department of Medical Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, People’s Republic of China

*These authors contributed equally to this work

Background: Carcinoma ex pleomorphic adenoma (CXPA), a very rare malignancy found mostly in the major salivary glands, has no established standardized treatment.

Case presentation: This report describes a 67-year-old male with advanced CXPA who was effectively treated by anlotinib. Pleomorphic adenoma of the submandibular gland was first diagnosed in 1976 after a surgical resection of a mass underneath the jaw. The patient underwent re-excision 3 years later due to a recurrent pleomorphic adenoma. CXPA was first diagnosed in 2016 after a surgical removal of the left submandibular mass. A lung nodule was found on a chest CT scan in January 2018. Following a CT-guided lung biopsy that demonstrated findings consistent with pulmonary metastasis, the patient underwent local therapy (microwave ablation and radioactive seed implantation) but suffered a recurrence of disease approximately 6 months later. Anlotinib was administered orally at a dose of 12 mg daily on a 2 weeks on/1 week off schedule. A partial response was observed after two cycles of treatment. The disease remains in continued partial response after completion of his sixth cycle.

Conclusion: This is the first report for anlotinib in treating CXPA. Further pre-clinical and clinical studies are needed to validate the efficacy and safety of anlotinib in the treatment of CXPA.

Keywords: pulmonary metastasis, chemotherapy, partial response, angiogenesis

Introduction
Salivary gland tumors are a morphologically and clinically diverse group of rare neoplasms originating in the major glands (parotid, submandibular, and sublingual) and minor glands (eg, oral mucosa, palate, uvula, pharynx, larynx, and paranasal sinuses). The most common type of benign salivary gland tumors is pleomorphic adenoma, which has a malignant potentiality. Malignant pleomorphic adenoma is a rare salivary gland neoplasm that is histologically identical to pleomorphic adenoma that inexplicably metastasize. According to the 2005 third histologic classification of the World Health Organization, there are three distinct clinicopathologic types for malignant pleomorphic adenoma: carcinoma ex pleomorphic adenoma (CXPA), carcinosarcoma, and metastasizing mixed tumor. CXPA is one of the three types of malignant pleomorphic adenoma arising from a primary or recurrent benign pleomorphic adenoma. The disease is very rare, for it has a prevalence rate of 5.6 cases per 100,000 malignant neoplasms and a yearly incidence rate of 0.17 tumors per 1 million
persons. The cancer is found predominantly in the parotid and submandibular glands.

No standardized treatment guideline is available for CXPA. Current treatment modalities consist of surgical resection, chemotherapy and radiotherapy. No targeted therapy options have been established for CXPA.

Anlotinib (Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd, People's Republic of China) is an oral receptor tyrosine kinase (RTK) inhibitor and targets multiple RTKs including vascular endothelial growth factor receptor type (VEGFR)1 to 3, EGFR, platelet-derived growth factor receptor α and β, and fibroblast growth factor receptor (FGFR)1–3. Anlotinib has been proved to be effective and safe as a third line treatment in patients with refractory advanced non-small cell lung cancer. There are also ongoing Phase I/II clinical trials for different types of sarcomas and carcinomas in China and other countries. However, to the best of our knowledge, no studies have been reported for anlotinib in treating CXPA. Here we report a case of recurrent CXPA which was effectively treated by anlotinib.

Written informed consent was obtained from the patient. Institutional approval was not required to publish the case details.

Case report
Clinical presentation

On July 8, 2016, a 67-year-old Chinese male was admitted to Jinan military general hospital due to a mass underneath the jaw. Neither numbness nor facial nerve weakness was reported. The patient received submandibular gland surgery in 1976 and 1979, respectively, to resect pleomorphic adenoma. Physical examination revealed that the mass had hard texture, unclear boundary, and a low degree of mobility. The patient’s treatment included removal of the left submandibular gland and concomitant neck dissection. Immunohistochemistry (IHC) revealed that tumor cells were positive to GFAP, CK5/6, S-100, CK8/CK18, and negative for CD117 and p63. Ki-67 proliferation index was 30–40%. (Figure 1A–C) No metastasis to the lymph nodes in the neck was found. The pathologic findings were supportive for the diagnosis of CXPA with a carcinomatous component of adenocarcinoma. Post-operative radiation therapy was carried out to target the operative bed (60 Gy in 30 fractions).

Fourteen months ago, the patient was re-hospitalized due to a lung nodule found on a chest CT scan. A CT-guided lung needle biopsy was performed. Histopathological

Figure 1 (A) Histology of primary carcinoma ex pleomorphic adenoma; (B) Immunohistochemistry showed that tumor cells were positive for CK8/18. (C) Immunohistochemistry showed that Ki 67 was 30–40%. (D) Histology of pulmonary metastasis. (E) Immunohistochemistry showed that tumor cells were positive for CK8/18. (F) Immunohistochemistry showed that Ki 67 was about 70%. (A–F) Original magnification, ×100, (A–C: primary carcinoma ex pleomorphic adenoma of the submandibular gland, D–F: pulmonary metastasis, A and D: hematoxylin-eosin).
examination revealed findings consistent with metastatic CXPA with adenocarcinoma component. On IHC, the tumor biopsy was positive for CK7, CK8/CK18, weak positive for villin, and negative for CK20, TTF-1, Napsin A, CK5/CK6 and p63. Ki67 was about 70% (Figure 1D–F). The patient underwent microwave ablation and radioactive seed implantation, respectively, but suffered a recurrence of disease approximately 6 months later. Anlotinib was administered orally at a dose of 12 mg daily on days 1–14 of a 21-day cycle. As shown in Figure 2, partial response was observed after two cycles of treatment. The disease remains in sustained partial response after completion of his sixth cycle.

**Discussion**

CXPA typically presents as a firm mass in the parotid or submandibular gland. It is very difficult to diagnose preoperatively. About a quarter of patients had a previously treated salivary pleomorphic adenoma. Treatment for CXPA remains challenging because conducting large randomized clinical trials is not realistic due to the entity’s low incidence. The major approach is surgical resection and radiotherapy. The value of chemotherapy is inclusive in advanced disease. There is very scant literature on chemotherapy in the treatment of CXPA. Several agents alone or in combination (vinorelbine, paclitaxel, cyclophosphamide, doxorubicin, and cisplatin) have been shown to be effective for some salivary gland malignancies. In a Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies, no response was observed in the patient with a malignant pleomorphic adenoma. In 2009, Lüers JC et al retrospectively analyzed 22 patients with CXPA of the parotid gland and showed that patients receiving chemotherapy even had a lower 5-year overall survival rate (50%) than those receiving no chemotherapy (63%). However, in a case report of CXPA from a Canadian group, chemotherapy with CAP (cyclophosphamide, doxorubicin, and cisplatin) result in an excellent clinical and radiologic response. Therefore, the role of chemotherapy in CXPA is still unclear. Due to the low number of patients, it is very difficult to conduct high-quality clinical trials for the disease. No targeted therapy options have been established for CXPA. Two case reports reported durable responses to treatment with trastuzumab in combination with chemotherapy in epidermal growth factor receptor 2 (HER2) positive patients. However, clinical trials of HER2 targeted therapies in malignant salivary tumors has been disappointing. In a Phase II study of HER2 positive advanced salivary gland cancers, the overall response to trastuzumab was only 7.1% (1/14). Another Phase II study of lapatinib showed no objective response in 36 patients.

![Figure 2](image_url) Chest CT scans before and after anlotinib treatment. (A and D): Before anlotinib treatment, two measurable tumor lesions were shown. (B and E) After two cycles of anlotinib treatment, a Partial response was observed. (C and F) After six cycles of anlotinib treatment, a continued partial response was observed. The white and black arrowheads aim at two measurable tumor lesions, respectively. Response assessment was based on RECIST guideline version 1.1.
Several genes associated with tumor angiogenesis, such as HGF-A, MET and COX2, were found to be highly expressed in CXPA.19,20 FGFR1–3, IGF1R, PDGFR β and EGFR were also reported to be over-expressed in CXPA.14,20,21 Anlotinib has a potent inhibitory action on tumor angiogenesis and was reported to target VEGFR1 to 3, EGFR, MET, PDGFR α and β, and FGFR1–4.4 Based on potential targetable pathways identified above, a multi-targeted tyrosine kinase inhibitor, like anlotinib, was a rational option for advanced CXPA.

In this case, the patient developed pulmonary metastasis 42 years after the first surgery. His disease progressed approximately 6 months after local therapy. Anlotinib was selected and resulted in an excellent response. No severe toxicity except grade 1 nausea was observed in the patient.

To the best of our knowledge, this is the first report for anlotinib in treating CXPA. Further pre-clinical and clinical studies are needed to validate the efficacy and safety of anlotinib in the treatment of CXPA.

Acknowledgments

We would like to acknowledge Dr Darmood Wei at the National Cancer Institute (USA) for providing his editorial expertise in this manuscript. This study was funded by Shandong Natural Science Foundation (Grant number: ZR2016HL28).

Disclosure

The authors report no conflicts of interest in this work.

References


